Clinical Trial Update: A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone [Phase 2]

View source ↗

Summary

A completed Phase II trial evaluating intermittent recombinant human interleukin-2 (rhIL-2) given intravenously or subcutaneously in HIV infection on HAART, com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Recombinant human interleukin-2 (rhIL-2) (interleukin-2)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 2 | Status: COMPLETED